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Department of Molecular Microbiology and Center for Women’s Infectious Disease Research, Washington University School of Medicine, Saint Louis, Missouri, USAa;
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ABSTRACT Gram-positive bacteria in the genus Enterococcus are a frequent cause of catheter-associated urinary tract infection
(CAUTI), a disease whose treatment is increasingly challenged by multiantibiotic-resistant strains. We have recently shown that
E. faecalis uses the Ebp pilus, a heteropolymeric surface fiber, to bind the host protein fibrinogen as a critical step in CAUTI
pathogenesis. Fibrinogen is deposited on catheters due to catheter-induced inflammation and is recognized by the N-terminal
domain of EbpA (EbpANTD), the Ebp pilus’s adhesin. In a murine model, vaccination with EbpANTD confers significant protec-
tion against CAUTI. Here, we explored the mechanism of protection using passive transfer of immune sera to show that antisera
blocking EbpANTD-fibrinogen interactions not only is prophylactic but also can act therapeutically to reduce bacterial titers of an
existing infection. Analysis of 55 clinical CAUTI, bloodstream, and gastrointestinal isolates, including E. faecalis, E. faecium,
and vancomycin-resistant enterococci (VRE), revealed a diversity of levels of EbpA expression and fibrinogen-binding efficiency
in vitro. Strikingly, analysis of 10 strains representative of fibrinogen-binding diversity demonstrated that, irrespective of EbpA
levels, EbpANTD antibodies were universally protective. The results indicate that, despite diversity in levels of fibrinogen binding,
strategies that target the disruption of EbpANTD-fibrinogen interactions have considerable promise for treatment of CAUTI.
IMPORTANCE Urinary catheterization is a routine medical procedure, and it has been estimated that 30 million Foley catheters
are used annually in the United States. Importantly, placement of a urinary catheter renders the patient susceptible to develop-
ing a catheter-associated urinary tract infection, accounting for 1 million cases per year. Additionally, these infections can lead
to serious complications, including bloodstream infection and death. Enterococcus strains are a common cause of these infec-
tions, andmanagement of enterococcal infections has beenmore difficult in recent years due to the development of antibiotic
resistance and the ability of strains to disseminate, resulting in a major threat in hospital settings. In this study, we developed an
antibiotic-sparing treatment that is effective against diverse enterococcal isolates, including vancomycin-resistant enterococci,
during catheter-associated urinary tract infections.
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It is estimated that 20% to 50% of all hospitalized patients receivea urinary catheter (1, 2), placing them at risk for developing a
catheter-associated urinary tract infection (CAUTI) (3). Short-
term urinary catheterization increases the risk of developing
CAUTI and other complications up to 80%, and prolonged cath-
eterization can increase the risk to 100% (4–6). CAUTI is the most
common cause of health-care-associated infection (HAI) world-
wide, accounting for 40% of all HAIs (7, 8), and often leads to
secondary bloodstream infection, with a 7-day mortality rate of
more than 30% (7, 9–11). Current guidelines recommend antibi-
otic treatments lasting 7 to 14 days to prevent CAUTI (8, 12);
however, control of CAUTIs has become a major challenge due to
the development and dissemination of antibiotic resistances
among the bacteria that cause HAI (9, 10).
A prominent example comes from bacteria in the genus En-
terococcus, which have emerged as a leading cause of HAI and
CAUTI (13, 14). Enterococcal HAI isolates are most commonly
Enterococcus faecalis and Enterococcus faecium, whose ability to
withstand heat, UV radiation, and aseptic solutions (14–16) al-
lows them to persist in the hospital ecology (14, 16). Treatment is
increasingly challenging because of their intrinsic and acquired
resistance to recently introduced antibiotics (15–17), and
vancomycin-resistant enterococci (VRE) along with multiply re-
sistant enterococcus (MRE) strains are now common in CAUTI
(18). Complete recovery from VRE infection may be prolonged
and in some cases requires 3 years (19). Currently, 30% of all
enterococcal HAI isolates are resistant to vancomycin (20), lead-
ing the Centers for Disease Control (CDC) to classify VRE as a
serious threat, recommending continuous monitoring and the de-
velopment of new therapeutic strategies (20).
New and improved treatment strategies will come from unrav-
eling the host and bacterial factors that shift enterococci from
commensalism to a pathogenic lifestyle. In this regard, we have
recently found that urinary catheterization in both mice and hu-
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mans elicits bladder inflammation, resulting in the release of fi-
brinogen into the bladder lumen (21) which then becomes depos-
ited onto the catheter (22, 23). In a murine model of CAUTI, we
found that released fibrinogen is critical for E. faecalis pathogen-
esis since (i) fibrinogen is used as a nutrient to promote entero-
coccal growth and (ii) E. faecalis exploits the fibrinogen-coated
catheters to form biofilms. In the absence of fibrinogen, the bac-
terium cannot bind directly to the catheter material (23). E. faeca-
lis expresses hair-like fibers called Ebp pili that are tipped with a
fibrinogen-binding adhesin, EbpA, which binds directly to fibrin-
ogen via its N-terminal domain (EbpANTD). Immunization with
EbpANTD, but not immunization with whole pili, the EbpA C-
terminal domain (EbpACTD), or other pilus subunits, protects
against CAUTI, reducing both catheter and bladder bacterial bur-
dens (23). Furthermore, protection correlated with the produc-
tion of antibodies that inhibit EbpANTD-fibrinogen binding in
several in vitro assays (23).
In this study, we evaluated the potential of EbpANTD-based
immunotherapies for translation to treatment of human CAUTI.
The contribution of EbpA to CAUTI pathogenesis caused by a
broad range of E. faecalis and E. faecium clinical isolates, the con-
tribution of fibrinogen binding to biofilm formation on catheters
recovered from human CAUTI, and the efficacy of EbpANTD-
based immunotherapy for treatment of CAUTI caused by a di-
verse collection of enterococcal clinical isolates were examined.
Our results indicate that EbpANTD-based immunotherapy is
broadly effective and suggest that this approach would be effective
for other enterococcal infections where fibrinogen is present.
RESULTS
E. faecalis colocalizeswithfibrinogenduringhumanCAUTI.To
explore the role of the E. faecalis-fibrinogen interaction in human
CAUTI, we examined the distribution of fibrinogen and E. faecalis
on catheters recovered from human CAUTI. The catheters were
obtained from patients undergoing both urological and nonuro-
logical procedures who developed an E. faecalis-positive urine cul-
ture prior to or after the placement of the catheter. Catheters were
removed at different indwelling times and were immediately
treated with fixative and then analyzed by fluorescence micros-
copy to assess patterns of fibrinogen deposition and enterococcal
binding. This examination revealed both extensive but nonuni-
form distribution of fibrinogen (anti-Fg; Fig. 1) and extensive
colonization of the catheter by E. faecalis (anti-E. faecalis [anti-
group D]) (Fig. 1). Furthermore, E. faecalis localized only to re-
gions with deposited fibrinogen (MERGE, Fig. 1), consistent with
a role for fibrinogen in promoting E. faecalis adherence and bio-
film formation on catheters.
Passive transfer of EbpANTD antibodies prevents CAUTI.
Vaccination with EbpA or EbpANTD protects mice from CAUTI
by E. faecalis OGIRF (23). Protection correlates with the develop-
ment of serum antibody that can block EbpA-fibrinogen binding
(23), suggesting an effector role for blocking antibody in protec-
tion. This hypothesis was tested by passive transfer of antisera to
naive mice that were then implanted with catheters and chal-
lenged with E. faecalis. Mice received either 1 intraperitoneal (i.p.)
dose of antisera at 4 h prior to catheter implantation and infection
(ci) or doses at 12 and 4 h prior to ci (Fig. 2A). Antiserum was from
mice immunized with EbpA or with EbpANTD or was serum from
mice mock vaccinated with phosphate-buffered saline (PBS).
Treated mice were then implanted with catheters and challenged
with 2  107 CFU of E. faecalis OG1RF. After 24 h postinfection
(hpi), urine samples were collected, and mice were sacrificed to
harvest bladders and catheters (Fig. 2A). Titration of bladder ho-
mogenates and urine indicated that anti-EbpA antibodies were
present following treatment with sera from immunized mice but
not but not following treatment with sera from mock-immunized
mice and that their levels were higher in the mice that received 2
doses (Fig. 2B and C). Treatment with either anti-EbpAFull or
anti-EbpANTD antisera significantly reduced the mean bacterial
burdens in the bladder (Fig. 2D) and catheter (Fig. 2E) of the
treated mice by ~3 logs compared to mice receiving serum from
mock-vaccinated mice (P  0.005). Anti-EbpAFull and anti-
EbpANTD treatments were equally effective, and those mice that
received a second dose of immune sera were more efficiently pro-
FIG 1 E. faecalis colocalized with Fg on human urinary catheters. Urinary catheters with an indwelling time of 18 h (A), 24 h (B and C), 8 days (D), or 9 days
(E) were recovered from patients with an enterococcal UTI. The presence and distribution of bacteria and fibrinogen were assessed by immunofluorescence using
antibody staining to detect fibrinogen (anti-Fg; green) and E. faecalis (anti-group D; red). As a negative control, a piece of the catheter was incubated with the
secondary antibody only to assess background fluorescence.
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tected, with a reduction of mean bladder and catheter titers of ~4
logs compared to control mice (P 0.0005). These data show that
the serum antibody targeting EbpANTD is the immune effector
conferring protection in EbpA-immunized mice.
Catheterization facilitates release of antibodies into the
bladder and urine. Serum antibody typically is not present at high
concentrations in the bladder or urine. However, catheterization
induces bladder inflammation, suggesting that, similarly to the
release of fibrinogen (21, 23), catheter-induced inflammation also
promotes the release of serum antibody into the bladder lumen.
To assess this, we compared the levels of release of anti-EbpANTD
antibodies into the bladders of uncatheterized and catheterized
mice at several time points prior to and after catheter implanta-
tion. Titers were also determined following challenge with
E. faecalis OG1RF (timeline, Fig. 3A). While anti-EbpANTD anti-
body was present in the serum of both catheterized and uncath-
eterized mice, antibody was detected in urine only following im-
plantation of catheters (Fig. 3B) and was present at the earliest
time point tested (4 h postcatheterization; Fig. 3B). Following in-
fection, anti-EbpANTD antibodies were detected in bladder ho-
mogenates from both catheterized and uncatheterized mice; how-
ever, titers were lower by ~2 logs in the uncatheterized group
(Fig. 3B). Taken together, these data show that catheterization and
not infection is the major factor resulting in the release of serum
antibody into the bladder.
Anti-EbpANTD antibody reduces titers of a preexisting infec-
tion. The therapeutic potential of anti-EbpANTD antibodies was
explored by testing whether passive transfer of immune serum
could reduce bacterial titers of a preexisting CAUTI. Mice were
implanted with catheters and challenged with E. faecalis OG1RF,
and infected mice were treated at 12 hpi with a single i.p. dose of
100 or 200l of a selected antiserum (timeline, Fig. 3C), including
anti-EbpAFull, anti-EbpANTD, anti-EbpACTD sera, serum from
PBS-mock-vaccinated mice, or an antiserum (anti-Streptococcus
group D antigen) that recognizes lipoteichoic acid (LTA), an
abundant but unrelated surface antigen. At 24 h post-antibody
treatment, mean bladder (Fig. 3D) and urine (Fig. 3E) CFUs were
significantly reduced by treatment with anti-EbpAFull or anti-
FIG 2 Passive immunization with anti-EbpAFull and anti-EbpANTD antibodies prevents E. faecalis CAUTI. Mice (n 10) were given a dose of 100l of PBS sera
or 100 l of anti-EbpAFull or anti-EbpANTD with a titer of 1 107. (A) Experimental timeline. Sac, time of mouse sacrifice. (B and C) Detection of EbpAFull and
EbpANTD antibodies in bladder (B) and in urine (C) analyzed by diluting each sample 1:100 before serial dilution. (D and E) Prophylaxis treatment performed
using 1 dose at 4 h prior infection (D) or 2 doses at 4 h prior infection and 12 h postinfection (hpi) (E). Values represent means SEM. The Mann-Whitney U test
was used for mouse experiments; P 0.05 was considered statistically significant. *, P 0.05; **, P 0.005; ***, P 0.0005; ****, P 0.00005; ns, values were
not statistically significantly different. The horizontal bar represents the median value. The horizontal broken line represents the limit of detection (LOD) of
viable bacteria. Animals that lost the catheter were not included in this work.
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EbpANTD sera but not by treatment with anti-EbpACTD, mock
sera, or anti-group D antigen antisera (P 0.0005). Therapeutic
efficacies were more pronounced in mice treated with the higher
doses of EbpAFull and anti-EbpANTD antisera (Fig. 3D and E).
These results demonstrate that anti-EbpA antibodies can clear a
preexisting infection, suggesting that the spectrum of anti-
EbpANTD-based immunotherapies can be expanded to include
therapeutic options. In addition, the fact that antibodies targeting
LTA were not protective emphasizes the unique vulnerability of
EbpANTD, validating EbpA-fibrinogen binding as a key step in
enterococcal pathogenesis.
E. faecalis infection does not confer protection against sub-
sequent infection. Hospitalized patients with an enterococcal in-
fection developed antibodies that recognized the Ebp pilus and its
individual structural subunits (24, 25). However, it has not been
demonstrated that these antibodies are protective against a subse-
quent infection. To assess this, mice were implanted with catheters
and infected with E. faecalis OG1RF or were mock infected with
PBS. To maximize the immune response and to prevent expulsion
of the catheter and the resulting loss of infection, mice were not
manipulated for the first 14 days hpi. Then, starting on day 14,
urine and blood samples were collected every 7 days or as other-
wise indicated (timeline, Fig. 4A) to assess levels of bacterial CFU
(Fig. 4B) and production of anti-E. faecalis and anti-EbpANTD
antibodies (see Fig. S1A and B in the supplemental material). At
day 35, mice were treated with vancomycin (0.5 g/liter in drinking
water) for 10 days and the clearance of CAUTI was monitored by
assessment of urine CFU, which became undetectable by day 56
FIG 3 Release of anti-EbpANTD antibodies into the bladder and urine is mediated by bladder inflammation upon catheterization, and passive transfer of
anti-EbpANTD antibodies reduced bacterial titers of an existing E. faecalis infection. (A) Experimental timeline. (B) Detection of anti-EbpANTD antibodies in
urine samples, bladder homogenates, and serum samples was analyzed by diluting each sample 1:100 before serial dilution. (C) Experimental timeline. Mice
(n 10) were implanted with catheters and challenged with 1 107 CFU ofE. faecalisOG1RF. A dose of PBS serum, anti-EbpAFull, anti-EbpANTD, anti-EbpACTD,
or anti-group D antibody was administered intraperitoneally (i.p.) at 12 h postinfection (hpi) (anti-EbpAFull, anti-EbpANTD, anti-EbpACTD, and anti-group D
antibody titers of 1 107). (D and E) Following 24 h of infection, bacterial burdens in bladder tissue (D) or recovered from catheters (E) were quantitated as the
number of CFU recovered. Values represent means SEM. The Mann-Whitney U test was used; P 0.05 was considered statistically significant. *, P 0.05; **,
P 0.005; ***, P 0.0005; ns, values were not statistically significantly different. The horizontal bar represents the median value. The horizontal broken line
represents the limit of detection of viable bacteria. Animals that lost the catheter were not included in this work.
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(Fig. 4B). At that time (Fig. 4A), mice were implanted with an
additional catheter and were rechallenged with the original
E. faecalis strain (OG1RF). When examined at 24 hpi, mean CFU
levels in bladder and mean CFU levels on catheters were not sig-
nificantly different between mice previously infected by E. faecalis
and those that were mock infected (Fig. 4C), despite the fact that
the former group developed antibodies against E. faecalis and Eb-
pANTD (see Fig. S1A and B). However, the antibody titers were ~3
logs lower than those developed in EbpANTD-vaccinated mice (see
Fig. S1A and B) or in rabbits conventionally vaccinated with
E. faecalis or EbpACTD (26). Furthermore, in contrast to serum
from EbpANTD-vaccinated mice, passive transfer of serum col-
lected from infected mice neither prevented (Fig. 4D) nor treated
(Fig. 4E) E. faecalis CAUTI and was no more effective than serum
FIG 4 A prior enterococcal infection does not confer protection against a subsequent infection. (A and B) Mice were mock infected (n 5) or infected with
E. faecalis OG1RF (n 15) (A); infection was followed by measuring the bacterial burden in urine (B). (C) After antibiotic treatment, mice were infected and
bacterial burdens in bladder tissue or recovered catheters were quantitated as the number of CFU recovered. (D to G) Mice were immunized with mock serum
(n  5), serum from infected mice (n  15 [D and E] or n  10 [F and G]), anti-EbpANTD antibodies (n  15 [D and E] or n  5 [F and G]), or diluted
anti-EbpANTD antibodies (n 5). Following 24 h of infection, bladders (D and F) and catheters (E and G) were harvested and bacterial burdens were quantified.
Values represent means SEM. The Mann-Whitney U test was used; P 0.05 was considered statistically significant. *, P 0.05; **, P 0.005; ***, P 0.0005;
ns, values were not statistically significantly different. The horizontal bar represents the median value. The horizontal broken line represents the limit of detection
of viable bacteria. Animals that lost the catheter were not included in this work.
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from mice mock vaccinated with PBS (Fig. 4D and E). Since it
seemed likely that this failure to provide protection was correlated
with the relatively low serum anti-EbpANTD titers that had devel-
oped during infection versus active vaccination, serum from
EbpANTD-vaccinated mice was diluted to a titer equivalent to that
obtained by infection (1  104) (see Fig. S1C). The diluted se-
rum from vaccinated mice was unable to protect against infection
and failed to reduce bladder (Fig. 4F) and catheter (Fig. 4G) titers
any better than serum from infected mice or from mice mock
vaccinated with PBS. This result confirms that the anti-EbpANTD
antibody concentration is crucial for protection and suggests that
anti-EbpANTD antibodies generated in infected hospitalized pa-
tients may not be protective against a subsequent infection.
The EbpA sequence is highly conserved across multiple en-
terococcal species. An ideal antivirulence therapeutic target
should be conserved in carriage and sequence across many patho-
genic strains and species. In this regard, the Ebp pilus has been
reported to be widely distributed across the members of the genus
Enterococcus (24, 27). To extend these observations, we examined
a diverse collection of 55 isolates to assess the presence and con-
servation of the Ebp pilus operon in clinical strains (see Table S1 in
the supplemental material). This analysis revealed that all three
genes that comprise the Ebp pilus were present in all 55 entero-
coccal genomes analyzed (Fig. 5A; see also Fig. S2A). Expanding
this analysis to a collection of genome sequences available in pub-
lic databases representing multiple enterococcal species, a hidden
Markov model was used to search for EbpA homologous se-
quences. A total of 480 peptides matching EbpA were identified
from eight Enterococcus species, including E. faecalis, E. faecium,
E. gallinarum, E. saccharolyticus, E. mundtii, E. hirae, E. casselifla-
FIG 5 Ebp pilus operon presence and analysis of EbpA conservation and expression and of its function in binding to Fg in clinical enterococcal strains. (A) Ebp
operon scheme. (B) Alignment of 137 unique EbpA peptide and nucleotide sequences by using a hidden Markov model. vWA, von Willebrand factor A. (C)
Pearson correlation statistical analysis was performed to measure the correlation between EbpA expression and Fg binding of each tested enterococcal strain
(n  3). Each dot represents the average of results from two independent experiments, each consisting of 3 biological replicates. As a negative control for the
expression of EbpA,Ebp pilus andEbpA strains were used, and as a negative control for Fg binding, the EbpA MIDAS mutant strain (AWAGA) was used. The
star symbols indicate the strains that were selected for additional in vivo analyses.
Flores-Mireles et al.

















vus, and E. flavescens. After filtering for unique sequences and
removal of sequences with low coverage (80%) of the EbpA
open reading frame were performed, the resulting 137 unique
peptide and nucleotide sequences were aligned (Fig. 5B). The re-
sulting gapped alignment shows that the sequences representing
the first ~100 amino acids of EbpA, comprising mainly the signal
sequence, are highly divergent between species of Enterococcus,
although they are generally well conserved within species (e.g.,
E. faecalis peptide sequences share 99.6% average pairwise identity
in the first 100 amino acids compared to 46.8% average pairwise
identity in the first 100 amino acids in all Enterococcus EbpA pep-
tide sequences). In contrast, the sequences of the EbpA N-
terminal domain (NTD) and C-terminal domain (CTD) are well
conserved across the members of the Enterococcus genus, with an
average pairwise identity of 73.7%, including 100% peptide se-
quence identity of the EbpANTD MIDAS motif (Fig. 5B) that is
required for binding to fibrinogen (23). This high degree of se-
quence similarity predicts conservation of the protective epitopes
recognized by anti-EbpANTD antibodies raised against EbpA of
E. faecalis OG1RF.
Surface-expressed EbpA correlates with fibrinogen binding
among enterococcal strains. Conservation of EbpA epitopes
predicts that an EbpA antisera raised against one strain will
recognize EbpA expressed by diverse strains. This prediction
was tested using antisera raised against EbpA of E. faecalis
OG1RF and a panel of clinical strains isolated from the urinary
tract (UT),the bloodstream, and the gastrointestinal tract (GIT),
including representatives of E. faecalis, E. faecium, E. gallinarum,
and VRE, as well as several unclassified enterococcal isolates (see
Table S1 in the supplemental material). Expression of cell surface
EbpA was evaluated by enzyme-linked immunosorbent assay
(ELISA) following in vitro culture under conditions known to
promote Ebp pilus expression in OG1RF (static culture in brain
heart infusion [BHI] medium for 18 h at 37°C). It was found that
the EbpA antiserum detected surface-expressed EbpA in all strains
tested (see Fig. S2A); however, there was a considerable range in
the amount of EbpA that was detected across the panel of isolates
(see Fig. S2B). To evaluate whether this range reflected differences
in the efficiency by which the antiserum recognized EbpA from
different strains versus differences in the levels of Ebp pilus ex-
pression, the panel of isolates was tested for fibrinogen binding.
This analysis also revealed a range of binding efficiencies of the
various isolates (see Fig. S2C). However, there was a positive (r
0.5385) and significant (P 0.0001) correlation between the de-
tected levels of surface-expressed EbpA and the levels of fibrino-
gen bound (Fig. 5C). Correlation between detection and function
suggests that there is heterogeneity in Ebp expression between
isolates rather than differential abilities of the anti-EbpA antise-
rum to detect heterologous EbpA proteins. Taken together, these
data show that EbpA is a ubiquitous factor expressed among en-
terococcal strains and species and that it has a conserved antigenic
profile.
EbpANTD-based immunotherapies can prevent and treat
CAUTI caused by diverse enterococcal isolates. The conserva-
tion of EbpA epitopes suggests that EbpANTD-based immunother-
apies would be effective against CAUTI caused by a wide range of
enterococcal strains and species. To test this, mice were immu-
nized with the OG1RF EbpANTD-based vaccine using a standard
protocol (100 g purified EbpANTD emulsified in Freund’s com-
plete adjuvant, with booster immunizations corresponding to the
original dose on weeks 4 and 8) or were subjected to mock vacci-
nation with PBS in adjuvant, as described previously (23). Mice
were challenged by a panel of strains selected to have high levels of
surface-expressed EbpA and of fibrinogen binding that also re-
flected clinical diversity, including a UTI isolate (EC#1), a VRE
blood isolate (EC#25), and an E. faecium GIT isolate (EC#30) (see
Table S1 in the supplemental material) (Fig. 5A; see also Fig. S2A
and B). Efficacy of protection was benchmarked against infection
by E. faecalis OG1RF. Four weeks after the second boost, mice
were implanted with catheters and challenged with 2 107 CFU of
the indicated strains. Analyzed at 24 hpi, it was found that all
tested strains were able to colonize the bladder and the catheter
(Fig. 6A). Furthermore, EbpANTD vaccination significantly re-
duced bladder and catheter burdens versus the levels seen with
mock-vaccinated mice for all strains examined (Fig. 6A).
Examined next was whether passive transfer of anti-EbpANTD
antibodies could treat CAUTI by reducing bacterial titers of an
ongoing infection. For this analysis, the number of clinical strains
tested was expanded to include those showing (i) high EbpA ex-
pression and high fibrinogen binding levels (EC#1, EC#25, EC#30,
EC#31, and EC#37); (ii) low EbpA expression and low fibrinogen
binding levels (EC#15, EC#43, and EC#49); and (iii) a low EbpA
expression level but a high fibrinogen binding level (EC#29 and
EC#32) (Fig. 5C; see also Fig. S2A and B in the supplemental
material). As before, these strains represented UTI, blood, and
GIT isolates. Mice were catheterized and challenged with 2 
107 CFU of the indicated strains; then, mice received 1 dose of
200 l of anti-EbpANTD or PBS-(mock)-vaccinated serum at
12 hpi. Examined at 24 hpi, all strains that highly expressed EbpA
were found to have colonized the bladder and catheter with CFU
levels equivalent to or higher than those measured for E. faecalis
OG1RF (Fig. 6B and C) and that treatment with EbpANTD anti-
bodies reduced bacterial titers by ~3 to 4 logs compared to the
levels seen with sera from control mice subjected to mock treat-
ment with PBS (Fig. 6B and C). Those strains that expressed low
levels of EbpA in vitro were also able to cause CAUTI and to col-
onize the bladder and catheter (Fig. 6D and E); however, their
colonization was not as efficient (104 to 105 CFU/ml) as that seen
with OG1RF and the strains expressing high levels of EbpA (106 to
107 CFU/ml). Analysis of two strains (EC#29 and EC#32) that
showed anomalous binding behavior in vitro (high levels of bind-
ing of Fg with only low-level expression of EbpA) revealed that
they were also able to colonize the bladder and catheter (105 to
106 CFU/ml). However, despite their low levels of EbpA expres-
sion in vitro, treatment with anti-EbpANTD antibodies was an ef-
fective therapy, reducing catheter and bladder CFUs ~1 to ~1.5
logs compared to PBS mock treatment serum controls (Fig. 6B
and C). Overall, these data show that EbpANTD-based immuno-
therapies have efficacy against a broad range of isolates.
DISCUSSION
In this study, we showed that passive immunization with anti-
EbpANTD antibodies is effective both as a prophylactic and as a
therapy for the reduction of bacterial titers in a murine CAUTI
model and that the level of protection correlated with the concen-
tration of anti-EbpANTD antibodies. More importantly, this ther-
apy was also protective against a broad range of urinary tract,
bloodstream, and GIT enterococcal clinical strains, which in-
cluded E. faecalis, E. faecium, and VRE. Our observation that, dur-
ing human CAUTI, E. faecalis colocalized with Fg deposited onto
Novel Treatment against Enterococcus Infections

















FIG 6 EbpANTD-based vaccine and anti-EbpANTD antibody treatment prevented and reduced bacterial titers of different enterococcal isolates. (A) Mice were
immunized and received two booster immunizations with doses of 100 g EbpANTD. Four weeks following the final immunization, mice were implanted with
catheters and challenged with 2 107 CFU of E. faecalis OG1RF (n 5) or with the indicated clinical enterococcal strains (n 5). Following 24 h of infection,
bacterial burdens in bladder tissue or recovered catheters were quantitated as the number of CFU recovered. org, organ. (B to E) To assess the therapeutic effect
of anti-EbpANTD antibodies against enterococcus-infected mice, antibodies were administered intraperitoneally 12 hpi (anti-EbpANTD antibody titer of 1 107).
Enterococcal strains were divided into two groups: (i) those that highly expressed EbpA and bound to Fg (B and C; n 5) and (ii) those that did not express EbpA
(n 10 [EC#15 and EC#43] and n 15 [EC#49]) or bind to Fg (D and E; n 15) under in vitro conditions. Bladder (B) and catheter (C) bacterial burdens were
quantified as described below. Values represent means SEM. The Mann-Whitney U test was used; P 0.05 was considered statistically significant. *, P 0.05;
**, P 0.005; ***, P 0.0005; ns, values were not statistically significantly different. The horizontal bar represents the median value. The horizontal broken line
represents the limit of detection of viable bacteria. Animals that lost the catheter were not included in this work.
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a urinary catheter recapitulated results from the murine CAUTI
model and from ex vivo analyses with catheters removed from
infected humans (28, 29) and suggests that EbpANTD-based im-
munotherapies can be directly translatable to treatment of human
disease.
Since it has been shown that EbpA is required for infection in
the murine model (23) and that mutation of the EbpA MIDAS
motif blocks both Fg binding and virulence (23, 30), it is likely that
EbpA-Fg interactions represent a key step in CAUTI pathogenesis
by directing initial adherence to the catheter surface. This is sup-
ported by studies showing colocalization of catheter Fg and bound
enterococci (22, 23). Thus, the most parsimonious model for pro-
tection would be via a steric mechanism where antibodies that
block binding to Fg prevent this initial attachment event. How-
ever, since passive immunization could act therapeutically against
an established infection, the mechanism of protection may be
more complex. Attachment and biofilm formation may be dy-
namic, involving multiple cycles of attachment and detachment.
Thus, when detached, enterococci may become susceptible to an-
tibodies that block reattachment. Alternatively, a multifactorial
mechanism could involve an EbpA-dependent opsonic activity or
an unknown EbpA activity in a domain adjacent to its Fg binding
site. Therefore, it will be of great interest to characterize the basis
of EbpANTD-mediated protection.
On the basis of our bioinformatic analysis, we found that Eb-
pANTD was highly conserved among diverse enterococcal species,
suggesting that multiple enterococcal lineages use a common
mechanism of CAUTI pathogenesis. This would explain the effec-
tiveness of the EbpANTD immunotherapies observed in the pres-
ent study. Other enterococcal species distributed across different
clades of the Enterococcus genus phylogeny (31, 32) have been
found to cause human infections, suggesting that these diverse
species may also have common traits for colonization, and viru-
lence, which may include EbpA.
Supporting the hypothesis of common mechanisms was the
overall correlation between EbpA expression in vitro and Fg bind-
ing across a panel of 55 strains. However, there were exceptions,
including two strains with a low level of EbpA expression but a
high level of fibrinogen binding. That these atypical strains colo-
nized bladder and catheter in the CAUTI model but were suscep-
tible to EbpANTD-based immunotherapy suggests that Ebp pili
play a critical role in CAUTI pathogenesis that cannot be compen-
sated for by other Fg-binding activities that can be expressed by
enterococci, including Fss proteins and PrpA (25, 33). It is possi-
ble that heterogeneity in regulation of Ebp means that pilus ex-
pression in vitro may not reflect levels in vivo. There are many
examples where in vitro conditions do not recapitulate in vivo
conditions (34, 35). Thus, it will be important to understand the
environmental cues in a catheterized bladder that play a role in
Ebp pilus expression.
Antibiotic treatment is the standard of care for an enterococcal
CAUTI but is increasingly unsuccessful. In fact, catheters often
must be removed because the patient does not respond to even
very rigorous antibiotic treatment. Treatment failure can have
other collateral effects, including native flora dysbiosis, in which
the elimination of gut commensals leads to the absence of
microbe-derived products such as flagella that stimulate secretion
of RegIII and other host defense molecules. This allows entero-
cocci to overgrow in the gut, causing inflammation, anastomotic
leakage, and bloodstream infection (28, 36, 37). Furthermore, pa-
tients hospitalized for long periods under conditions of antibiotic
treatment are susceptible to infection by E. faecium, which is fre-
quently resistant to vancomycin and ampicillin (14, 16, 17) and
under these conditions can become the dominant flora (16, 29).
Thus, alternative therapies are needed to treat and to prevent the
evolution of multiply resistant enterococci. Antibiotic-sparing
therapies targeting enterococcus-Fg interaction may hold consid-
erable promise, and since EbpA is highly conserved and important
for colonization, it may represent the ideal target for this ap-
proach. Its critical role also suggests that enterococci must protect
it from the immune response in order to cause persistent infec-
tions. Consistent with this, mice with E. faecalis CAUTI generated
low titers of anti-EbpANTD antibodies, which did not confer resis-
tance against reinfection. Since EbpA is a minor component of a
large heteropolymer, it is unlikely to be the immunodominant
component of the pilus fiber. A similar strategy of compartmen-
talizing the adhesive activity to a single subunit of a large het-
eropolymer is used by uropathogenic Escherichia coli to protect
the adhesive subunit of its type 1 pilus adhesin (38). Alternatively,
E. faecalis may further exploit its ability to interact with Fg to coat
both individual cells and biofilm with a host protein in order to
obtain immune privilege and evade recognition by the immune
response. Thus, any strategy targeting EbpA must defeat the
mechanisms that enterococci have evolved to protect this Achilles
heel from the host’s protective responses. Fibrinogen is found in
the bloodstream and is a marker of vascular rupture and respon-
sible for coagulation, fibrosis, protection from infections, and
other functions (39). Based on the importance of fibrinogen for
E. faecalis colonization via EbpA and the conservation of EbpA
among enterococcal strains and given that fibrinogen is present
during in other situations as infective endocarditis, bacteremia,
and intra-abdominal and surgical-site infections (40), it is feasible
that fibrinogen could be a general factor for the pathogenesis of
Enterococcus spp. It may also represent a common strategy for
biofilm formation and colonization of catheters, indwelling de-
vices, or tissues at other anatomical sites, including venous cath-
eters, orthopedic implants, and damaged heart valves in endocar-
ditis (41). Thus, EbpA-Fg interactions represent a vulnerability
that can be exploited for intervention in enterococcal infections
where Fg is present.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Unless otherwise specified,
E. faecalis strain OG1RF and its derivatives and enterococcal strains were
grown overnight on brain heart infusion broth (BHI) (BD Company) and
were inoculated from a single bacterial colony grown on BHI agar plates.
Liquid cultures were grown statically at 37°C for 18 h or as otherwise
indicated. Bacterial strains are listed in Table S1 in the supplemental ma-
terial.
General cloning techniques. Bacterial genomic DNA (gDNA) was
isolated by using a Wizard genome DNA purification kit (Promega Corp).
Primers were purchased from Integrated DNA Technology. Phusion High
Fidelity DNA polymerase was purchased from New England Biolabs and
used according to the methods described by the manufacturer.
Antibodies used in this study. The primary antibodies used in the
study were rabbit anti-Streptococcus group D antigen (anti-E. faecalis li-
poteichoic acid) (Lee Laboratories) (26) and mouse anti-EbpAFull, mouse
anti-EbpANTD, and mouse anti-EbpACTD (generated in this study). The
secondary antibodies used in the study were IRDye 800CW donkey anti-
goat (catalog no. 926-32213) and IRDye 680LT goat anti-rabbit (catalog
no. 926-68021) antibodies from Li-Cor Biosciences and horseradish per-
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oxidase (HRP)-conjugated goat anti-mouse and goat anti-rabbit antisera
from KPL.
Human urinary catheter analysis. The human urinary catheter was
collected per the study approval from the Washington University School
of Medicine Internal Review Board (approval #201410058). After collec-
tion, the catheter was cut into 10-cm-long segments and the segments
were fixed with formalin for 1 h and washed (3 times) with PBS. For
analysis, the first 10 cm of the catheter’s tip was blocked by overnight
incubation at 4°C with 1.5% bovine serum albumin (BSA)– 0.1% sodium
azide–PBS (BB) and then washed three times for 5 min each time with
PBS-T (PBS containing 0.05% Tween 20). A 15-ml solution containing
goat anti-human fibrinogen and rabbit anti-Streptococcus group D (1:500)
antisera in dilution buffer (PBS with 0.05% Tween 20, 0.1% BSA, and
0.5% methyl -D-mannopyronoside) was added, and the reaction mix-
ture was incubated at room temperature for 2 h. Then, it was washed (3
times) for 5 min each time with PBS-T and incubated with donkey anti-
goat IRDye 800CW (diluted 1:10,000) in dilution buffer for 45 min at
room temperature. Following an additional 3 washes with PBS-T, cathe-
ters were examined for infrared signal using an Odyssey Imaging System
(Li-Cor Biosciences). Autofluorescence was assessed in nonimplanted
catheters and catheters not incubated with the primary antibody and was
minimal.
Mouse catheter implantation and infection. The mice used in this
study were 6-week-old female wild-type C57BL/6Ncr mice purchased
from Charles River Laboratories. Mice were subjected to transurethral
implantation and inoculated as previously described (34). Mice were
anesthetized by inhalation of isoflurane and implanted with a 5-mm
length of platinum-cured silicone catheter. When indicated, mice were
infected immediately following catheter implantation with 50 l of ~2
107 CFU of bacteria in PBS introduced into the bladder lumen by trans-
urethral inoculation as previously described (34). To harvest the catheters
and organs, mice were sacrificed at the desired time points by cervical
dislocation after anesthesia inhalation, and the bladders were aseptically
harvested. Subsequently, the silicone implant was retrieved from the blad-
der, when present. All studies and procedures were approved by the Ani-
mal Studies Committee at the Washington University School of Medicine.
Active and passive immunization of mice. Mice were immunized as
previously described (23). Groups of 10 mice were used for each vaccine
dose. One hundred micrograms of EbpA proteins or PBS was emulsified
with either Freund’s complete adjuvant (first vaccination) or Freund’s
incomplete adjuvant (boosts). Mice were vaccinated intramuscularly and
then with the same dose at 4 and 8 weeks. Mouse sera were collected prior
to immunization and every week after to determine the antibody re-
sponse. At 4 weeks after the second boost, mice were implanted with
catheters and challenged with ~2  107 CFU of E. faecalis OG1RF or
clinical enterococcal isolates. Mice were sacrificed at 24 hpi to determine
bacterial titers in the bladder and catheters, as described above. For the
passive immunization experiments, the specified antiserum was adminis-
tered via intraperitoneally injection. Specific antisera, concentrations, and
doses are specified in the timeline for each experiment performed in this
study. Control groups were administered PBS-mock vaccination serum or
an antiserum targeting LTA (anti-Streptococcus group D antigen antise-
rum). Mice were subjected to catheter implantation and challenged as
described before.
Determination of antibody responses in mice. A 100-l volume of
E. faecalis OG1RF at an optical density at 600 (OD600) of 0.5 or 10 g of
EbpA proteins was used to coat Immulon 4HBX flat-bottom microplates
(Thermo, Fisher) overnight at 4°C. Plates were washed (3 times) with
PBS-T to remove unbound bacteria or protein and blocked for 2 h with
BB. Bladder homogenates and urine and serum samples from infected or
vaccinated mice were diluted 1:100 in dilution buffer before serial dilu-
tions. Then, 100 l of the diluted samples was added into the plate and
incubated for 2 h at room temperature. After the incubation, the plates
were washed (3 times) with PBS-T, followed by a 1-h incubation with
HRP-conjugated goat anti-mouse antisera (1:2,000), and were then
washed (3 times) with PBS-T. Detection was performed using a TMB
substrate reagent set (BD catalog no. 555214). The reaction mixtures were
incubated for 5 min to allow color to develop, and the reactions were then
stopped by the addition of 1.0 M sulfuric acid. The absorbance was deter-
mined at 450 nm. Titers were defined by the last dilution with an A450 of at
least 0.2.
Presence of Ebp pilus operon in enterococcal strains. Bacterial
strains were grown overnight in BHI broth, and gDNA was isolated by
following the manufacturer’s instructions. The ebp pilus operon was PCR
amplified by using two sets of primers. The sets of primers were designed
from a highly conserved region that came from an alignment of 500 ebp
operon nucleotide sequences from different Enterococcus species, includ-
ing E. faecalis, E. faecium, E. gallinarum, E. saccharolyticus, E. mundtii,
E. hirae, E. casseliflavus, and E. flavescens. The first set of primers,
ALFM65-ALFM80, amplifies 3,835 bp from 422 bp upstream of the ebpA
gene to the first 98 bp of ebpB (ALFM65 [F], 5=-GCAAGTTCTTTTTTA
GTCATCCA-3=; ALFM80 [R], 5=-TGAACGCTTGCTTGCGATGCCTC
TG-3=). The second set of primers, ALFM70-ALFM85, amplifies 4,626 bp
from the last 552 bp of ebpA to 104 bp downstream of ebpC gene (ALFM70
[F], 5=-GGAAATTATGAATTTACTGTTGATAAATATGG-3=; ALFM85
[R], 5=-ACTTCATTGCTTCCTCC-3=). Each PCR product was visualized
by using electrophoresis and 1% Tris-borate-EDTA (TBE) agarose gels.
Expression of EbpA in the cell surface of enterococcal strains. Sur-
face expression of EbpA by clinical and laboratory enterococcal strains
was detected by whole-cell ELISA as previously described (23). Bacterial
strains were grown for 12 h in BHI broth, washed (3 times) with PBS, and
normalized to an OD600 of 0.5. Then, bacterial cells were washed and
resuspended with 50 mM carbonate buffer (pH 9.6) containing 0.1%
sodium azide and 100 l of the each bacterial solution was used to coat
Immulon 4HBX microtiter plates overnight at 4°C. Plates were washed
with PBS-T to remove unbound bacteria and blocked for 2 h with BB
followed by washes performed with PBS-T. EbpA surface expression was
detected using mouse anti-EbpAFull antisera, which was diluted 1:100 in
dilution buffer before serial dilutions were performed as described above.
A 100-l volume was added to the plate, and the reaction mixture was
incubated for 2 h. After the incubation, the plates were washed with PBS-T
followed by 1 h of incubation with HRP-conjugated goat anti-rabbit an-
tisera (1:2,000) and were then washed with PBS-T. Detection was per-
formed using a TMB substrate reagent set. The reaction mixtures were
incubated, developed, and measured as described above. As an additional
control, rabbit anti-Streptococcus group D antiserum was used to verify
that whole cells of all strains were bound to the microtiter plates at similar
levels.
Whole-bacterial binding to fibrinogen. To determine whether en-
terococcal strains adhere to immobilized fibrinogen as previously de-
scribed (23), Immulon 4HBX microplates were coated overnight at 4°C
with 100 g/ml of human fibrinogen that was free of plasminogen and
von Willebrand factor (Enzyme Research Laboratory). The plates were
blocked for an hour with BB, followed with PBS washes (performed 3
times for 5 min each time). Bacterial strains were grown for 12 h in BHI
broth, were normalized to an OD600 of 0.5, and then were washed and
resuspended in PBS. A total of 100 l of bacteria was added to the coated
wells and incubated for an hour at 37°C, followed by PBS washes per-
formed using the wash function of a microplate reader (ELX405 select
CW; Biotek Instruments) to remove the unbound bacteria. Next, bacterial
cells were fixed with formalin for 20 min at room temperature, followed
by washes performed with PBS-T, and were then blocked overnight at 4°C
with BB, and PBS-T washes were performed. Then, plates were incubated
for an hour at room temperature with rabbit anti-Streptococcus group D
antigen antisera (1:500). Plates were washed with PBS-T, incubated with
Odyssey secondary antibody (goat anti-rabbit IRDye 680LT, diluted
1:10,000 in dilution buffer) for 45 min at room temperature, and washed
with PBS-T. As a final step, the plates were scanned for infrared signal
using an Odyssey imaging system (Li-Cor Biosciences).
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EbpA sequence analysis. Using the amino acid sequence of E. faecalis
OG1RF as a query, we identified homologs of EbpA in the UniProtKB
database using the PHMMER webserver (42, 43). Nucleotide sequences of
the genes encoding matches were then retrieved from the Ensembl data-
base (44) using their unique identifiers. Homologous gene sequences were
then filtered to remove duplicate nucleotide sequences and nucleotide
sequences which did not cover 80% of the OG1RF gene sequence.
Amino acid sequences of the unique EbpA homologs were then aligned
using the MAFFT algorithm (45) and the BLOSUM62 scoring matrix, and
a corresponding codon-based alignment of the nucleotide sequences was
constructed using PAL2NAL (46). The percent identity of these align-
ments was then visualized using sliding windows of 20 amino acids and 60
nucleotides for the protein and gene sequences, respectively.
Statistical analyses. Data from multiple experiments were pooled.
Two-tailed Mann-Whitney U tests were performed with GraphPad Prism
5 software (GraphPad Software, San Diego, CA) for all comparisons de-
scribed for CAUTI experiments. Antibody titration, expression of EbpA,
and binding assays were analyzed by using a paired t test to evaluate the
significance of differences. To measure the strength of the linear relation-
ship between EbpA expression and fibrinogen binding, a Pearson corre-
lation analysis was performed. Values represent means standard errors
of the means (SEM) derived from results of at least 3 independent exper-
iments (*, P 0.05; **, P 0.005; ***, P 0.0005; ****, P 0.00005; ns,
difference not statistically significant).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org/
lookup/suppl/doi:10.1128/mBio.01653-16/-/DCSupplemental.
Figure S1, TIF file, 16.7 MB.
Figure S2, TIF file, 27.7 MB.
Table S1, DOCX file, 0.04 MB.
ACKNOWLEDGMENTS
We thank members of the S.J.H. and M.G.C. laboratories for their helpful
suggestions and insightful comments. Special thanks to our clinical coor-
dinator, Aleksandra Klim, and to the urology team.
This work was supported by grant 1F32DK104516-01 to A.L.F.-M.
and by grants R01-DK051406, R01-AI108749-01, and P50-DK0645400 to
A.L.F.-M., J.N.W., H.L.S.IV, J.S.P., M.G.C., and S.J.H. from the National
Institute of Allergy and Infectious Diseases (NIAID) and National Insti-
tute of Diabetes and Digestive and Kidney Diseases (NIDDK).
FUNDING INFORMATION
This work, including the efforts of Ana L. Flores-Mireles, Jennifer N.
Walker, Scott J. Hultgren, and Michael G. Caparon, was funded by HHS |
NIH | National Institute of Allergy and Infectious Diseases (NIAID) (R01-
AI108749-01). This work, including the efforts of Ana L. Flores-Mireles,
was funded by HHS | NIH | National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK) (1F32DK104516-01). This work, includ-
ing the efforts of Ana L. Flores-Mireles, Jennifer N. Walker, Henry L.
Schreiber, Jerry S. Pinkner, and Scott J. Hultgren, was funded by HHS |
NIH | National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) (R01-DK051406). This work, including the efforts of Ana L.
Flores-Mireles, Jennifer N. Walker, Henry L. Schreiber, Jerry S. Pinkner, and
Scott J. Hultgren, was funded by HHS | NIH | National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK) (P50-DK0645400).
REFERENCES
1. Saint S, Wiese J, Amory JK, Bernstein ML, Patel UD, Zemencuk JK,
Bernstein SJ, Lipsky BA, Hofer TP. 2000. Are physicians aware of which
of their patients have indwelling urinary catheters? Am J Med 109:
476 – 480. http://dx.doi.org/10.1016/S0002-9343(00)00531-3.
2. Jain P, Parada JP, David A, Smith LG. 1995. Overuse of the indwelling
urinary tract catheter in hospitalized medical patients. Arch Intern Med
155:1425–1429.
3. de Oliveira Conterno L, Lobo JA, Masson W. 2011. The excessive use of
urinary catheters in patients hospitalized in university hospital wards. Rev
Esc Enferm USP 45:1089 –1096. (In Portuguese.)
4. Parker D, Callan L, Harwood J, Thompson DL, Wilde M, Gray M. 2009.
Nursing interventions to reduce the risk of catheter-associated urinary
tract infection. Part 1: catheter selection. J Wound Ostomy Continence
Nurs 36:23–34. http://dx.doi.org/10.1097/01.WON.0000345173
.05376.3e.
5. Maki DG, Tambyah PA. 2001. Engineering out the risk for infection with
urinary catheters. Emerg Infect Dis 7:342–347. http://dx.doi.org/10.3201/
eid0702.700342.
6. Willson M, Wilde M, Webb ML, Thompson D, Parker D, Harwood J,
Callan L, Gray M. 2009. Nursing interventions to reduce the risk of
catheter-associated urinary tract infection: Part 2: staff education, moni-
toring, and care techniques. J Wound Ostomy Continence Nurs 36:
137–154. http://dx.doi.org/10.1097/01.WON.0000347655.56851.04.
7. Tambyah PA, Maki DG. 2000. Catheter-associated urinary tract infection
is rarely symptomatic—a prospective study of 1,497 catheterized patients.
Arch Intern Med 160:678 – 682.
8. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice
JC, Saint S, Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE; Infectious
Diseases Society of America. 2010. Diagnosis, prevention, and treatment
of catheter-associated urinary tract infection in adults: 2009 International
Clinical Practice Guidelines from the Infectious Diseases Society of Amer-
ica. Clin Infect Dis 50:625– 663.
9. Warren JW. 1997. Catheter-associated urinary tract infections. Infect Dis
Clin North Am 11:609 – 622. http://dx.doi.org/10.1016/S0891
-5520(05)70376-7.
10. Trautner BW, Darouiche RO. 2004. Catheter-associated infections:
pathogenesis affects prevention. Arch Intern Med 164:842– 850. http://
dx.doi.org/10.1001/archinte.164.8.842.
11. Melzer M, Welch C. 2013. Outcomes in UK patients with hospital-
acquired bacteraemia and the risk of catheter-associated urinary tract in-
fections. Postgrad Med J 89:329 –334. http://dx.doi.org/10.1136/
postgradmedj-2012-131393.
12. Jarrell AS, Wood GC, Ponnapula S, Magnotti LJ, Croce MA, Swanson
JM, Boucher BA, Fabian TC. 2015. Short-duration treatment for
catheter-associated urinary tract infections in critically ill trauma patients.
J Trauma Acute Care Surg 79:649 – 653. http://dx.doi.org/10.1097/
TA.0000000000000822.
13. Orsi GB, Ciorba V. 2013. Vancomycin resistant enterococci healthcare
associated infections. Ann Ig 25:485– 492.
14. Van Tyne D, Gilmore MS. 2014. Friend turned foe: evolution of entero-
coccal virulence and antibiotic resistance. Annu Rev Microbiol 68:
337–356. http://dx.doi.org/10.1146/annurev-micro-091213-113003.
15. Cardoso T, Ribeiro O, Aragão IC, Costa-Pereira A, Sarmento AE. 2012.
Additional risk factors for infection by multidrug-resistant pathogens in
healthcare-associated infection: a large cohort study. BMC Infect Dis 12:
375. http://dx.doi.org/10.1186/1471-2334-12-375.
16. Miller WR, Munita JM, Arias CA. 2014. Mechanisms of antibiotic resis-
tance in enterococci. Expert Rev Anti Infect Ther 12:1221–1236. http://
dx.doi.org/10.1586/14787210.2014.956092.
17. Arias CA, Murray BE. 2012. The rise of the enterococcus: beyond vanco-
mycin resistance. Nat Rev Microbiol 10:266 –278. http://dx.doi.org/
10.1038/nrmicro2761.
18. Escaut L, Bouam S, Frank-Soltysiak M, Rudant E, Saliba F, Kassis N,
Presiozi P, Vittecoq D. 2013. Eradication of an outbreak of vancomycin-
resistant enterococcus (VRE): the cost of a failure in the systematic screen-
ing. Antimicrob Resist Infect Contr 2:18. http://dx.doi.org/10.1186/2047
-2994-2-18.
19. Byers KE, Anglim AM, Anneski CJ, Farr BM. 2002. Duration of coloni-
zation with vancomycin-resistant enterococcus. Infect Control Hosp Epi-
demiol 23:207–211. http://dx.doi.org/10.1086/502036.
20. Team EE. 2013. CDC publishes report on antibiotic resistance threats in
the United States for the first time. Euro Surveill 18:28.
21. Guiton PS, Hannan TJ, Ford B, Caparon MG, Hultgren SJ. 2013.
Enterococcus faecalis overcomes foreign body-mediated inflammation to
establish urinary tract infections. Infect Immun 81:329 –339. http://
dx.doi.org/10.1128/IAI.00856-12.
22. Flores-Mireles AL, Walker JN, Bauman TM, Potretzke AM, Schreiber
HL, Park AM, Pinkner JS, Caparon MG, Hultgren SJ, Desai A. 2016.
Fibrinogen release and deposition on urinary catheters placed during uro-
logic procedures. J Urol 196:416 – 421 http://dx.doi.org/10.1016/
j.juro.2016.01.100.
Novel Treatment against Enterococcus Infections

















23. Flores-Mireles AL, Pinkner JS, Caparon MG, Hultgren SJ. 2014. EbpA
vaccine antibodies block binding of Enterococcus faecalis to fibrinogen to
prevent catheter-associated bladder infection in mice. Sci Transl Med
6:254ra127. http://dx.doi.org/10.1126/scitranslmed.3009384.
24. Nallapareddy SR, Singh KV, Sillanpää J, Garsin DA, Höök M, Erland-
sen SL, Murray BE. 2006. Endocarditis and biofilm-associated pili of
Enterococcus faecalis. J Clin Invest 116:2799 –2807. http://dx.doi.org/
10.1172/JCI29021.
25. Sillanpää J, Nallapareddy SR, Houston J, Ganesh VK, Bourgogne A,
Singh KV, Murray BE, Höök M. 2009. A family of fibrinogen-binding
MSCRAMMs from Enterococcus faecalis. Microbiology 155:2390 –2400.
http://dx.doi.org/10.1099/mic.0.027821-0.
26. Kau AL, Martin SM, Lyon W, Hayes E, Caparon MG, Hultgren SJ. 2005.
Enterococcus faecalis tropism for the kidneys in the urinary tract of
C57BL/6J mice. Infect Immun 73:2461–2468. http://dx.doi.org/10.1128/
IAI.73.4.2461-2468.2005.
27. Nallapareddy SR, Murray BE. 2008. Role played by serum, a biological
cue, in the adherence of Enterococcus faecalis to extracellular matrix pro-
teins, collagen, fibrinogen, and fibronectin. J Infect Dis 197:1728 –1736.
http://dx.doi.org/10.1086/588143.
28. Shogan BD, Belogortseva N, Luong PM, Zaborin A, Lax S, Bethel C,
Ward M, Muldoon JP, Singer M, An G, Umanskiy K, Konda V,
Shakhsheer B, Luo J, Klabbers R, Hancock LE, Gilbert J, Zaborina O,
Alverdy JC. 2015. Collagen degradation and MMP9 activation by Entero-
coccus faecalis contribute to intestinal anastomotic leak. Sci Transl Med
7:286ra268. http://dx.doi.org/10.1126/scitranslmed.3010658.
29. Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA,
Hujer AM, Hutton-Thomas RA, Whalen CC, Bonomo RA, Rice LB.
2000. Effect of antibiotic therapy on the density of vancomycin-resistant
enterococci in the stool of colonized patients. N Engl J Med 343:
1925–1932. http://dx.doi.org/10.1056/NEJM200012283432604.
30. Nielsen HV, Guiton PS, Kline KA, Port GC, Pinkner JS, Neiers F,
Normark S, Henriques-Normark B, Caparon MG, Hultgren SJ. 2012.
The metal ion-dependent adhesion site motif of the Enterococcus faecalis
EbpA pilin mediates pilus function in catheter-associated urinary tract
infection. mBio 3:e00177-12. http://dx.doi.org/10.1128/mBio.00177-12.
31. Lebreton F, Willems RJL, Gilmore MS. 2014. Enterococcus diversity,
origins in nature, and gut colonization. In Gilmore MS, Clewell DB, Ike Y,
Shankar N (ed), Enterococci: from commensals to leading causes of drug
resistant infection. Massachusetts Eye and Ear Infirmary, Boston, MA.
32. Gilmore MS, Lebreton F, van Schaik W. 2013. Genomic transition of
enterococci from gut commensals to leading causes of multidrug-resistant
hospital infection in the antibiotic era. Curr Opin Microbiol 16:10 –16.
http://dx.doi.org/10.1016/j.mib.2013.01.006.
33. Guzmán Prieto AM, Urbanus RT, Zhang X, Bierschenk D, Koekman
CA, van Luit-Asbroek M, Ouwerkerk JP, Pape M, Paganelli FL, Wobser
D, Huebner J, Hendrickx AP, Bonten MJ, Willems RJ, van Schaik W.
2015. The N-terminal domain of the thermo-regulated surface protein
PrpA of Enterococcus faecium binds to fibrinogen, fibronectin and plate-
lets. Sci Rep 5:18255. http://dx.doi.org/10.1038/srep18255.
34. Guiton PS, Hung CS, Hancock LE, Caparon MG, Hultgren SJ. 2010.
Enterococcal biofilm formation and virulence in an optimized murine
model of foreign body-associated urinary tract infections. Infect Immun
78:4166 – 4175. http://dx.doi.org/10.1128/IAI.00711-10.
35. Guiton PS, Hung CS, Kline KA, Roth R, Kau AL, Hayes E, Heuser J,
Dodson KW, Caparon MG, Hultgren SJ. 2009. Contribution of autolysin
and sortase A during Enterococcus faecalis DNA-dependent biofilm devel-
opment. Infect Immun 77:3626 –3638. http://dx.doi.org/10.1128/
IAI.00219-09.
36. Van Tyne D, Gilmore MS. 2014. A delicate balance: maintaining mutu-
alism to prevent disease. Cell Host Microbe 16:425– 427. http://
dx.doi.org/10.1016/j.chom.2014.09.019.
37. Kinnebrew MA, Ubeda C, Zenewicz LA, Smith N, Flavell RA, Pamer
EG. 2010. Bacterial flagellin stimulates Toll-like receptor 5-dependent de-
fense against vancomycin-resistant enterococcus infection. J Infect Dis
201:534 –543. http://dx.doi.org/10.1086/650203.
38. Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS,
Burlein J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ. 1997.
Prevention of mucosal Escherichia coli infection by FimH-adhesion-based
systemic vaccination. Science 276:607– 611. http://dx.doi.org/10.1126/
science.276.5312.607.
39. Jennewein C, Tran N, Paulus P, Ellinghaus P, Eble JA, Zacharowski K.
2011. Novel aspects of fibrin(ogen) fragments during inflammation. Mol
Med 17:568 –573. http://dx.doi.org/10.2119/molmed.2010.00146.
40. Nomura R, Otsugu M, Naka S, Teramoto N, Kojima A, Muranaka Y,
Matsumoto-Nakano M, Ooshima T, Nakano K. 2014. Contribution of
the interaction of Streptococcus mutans serotype k strains with fibrinogen
to the pathogenicity of infective endocarditis. Infect Immun 82:
5223–5234. http://dx.doi.org/10.1128/IAI.02164-14.
41. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clin-
ically relevant microorganisms. Clin Microbiol Rev 15:167–193. http://
dx.doi.org/10.1128/CMR.15.2.167-193.2002.
42. Finn RD, Clements J, Arndt W, Miller BL, Wheeler TJ, Schreiber F,
Bateman A, Eddy SR. 2015. HMMER web server: 2015 update. Nucleic
Acids Res 43:W30 –W38. http://dx.doi.org/10.1093/nar/gkv397.
43. Finn RD, Clements J, Eddy SR. 2011. HMMER web server: interactive
sequence similarity searching. Nucleic Acids Res 39:W29 –W37. http://
dx.doi.org/10.1093/nar/gkr367.
44. Cunningham F, Amode MR, Barrell D, Beal K, Billis K, Brent S,
Carvalho-Silva D, Clapham P, Coates G, Fitzgerald S, Gil L, Girón CG,
Gordon L, Hourlier T, Hunt SE, Janacek SH, Johnson N, Juettemann T,
Kähäri AK, Keenan S, Martin FJ, Maurel T, McLaren W, Murphy DN,
Nag R, Overduin B, Parker A, Patricio M, Perry E, Pignatelli M, Riat
HS, Sheppard D, Taylor K, Thormann A, Vullo A, Wilder SP, Zadissa
A, Aken BL, Birney E, Harrow J, Kinsella R, Muffato M, Ruffier M,
Searle SM, Spudich G, Trevanion SJ, Yates A, Zerbino DR, Flicek P.
2015. Ensembl 2015. Nucleic Acids Res 43:D662–D669. http://dx.doi.org/
10.1093/nar/gku1010.
45. Katoh K, Misawa K, Kuma K, Miyata T. 2002. MAFFT: a novel method
for rapid multiple sequence alignment based on fast Fourier transform.
Nucleic Acids Res 30:3059 –3066. http://dx.doi.org/10.1093/nar/gkf436.
46. Suyama M, Torrents D, Bork P. 2006. PAL2NAL: robust conversion of
protein sequence alignments into the corresponding codon alignments.
Nucleic Acids Res 34:W609 –W612. http://dx.doi.org/10.1093/nar/
gkl315.
Flores-Mireles et al.









ber 23, 2016 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
